COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its ongoing Phase 1b trials of ipafricept (FZD8-Fc, OMP-54F28) and vantictumab (anti-Fzd, OMP-18R5) at the European Society of Medical Oncology (ESMO) 2016 Congress.
Ipafricept and vantictumab are first-in-class Wnt pathways inhibitors that are each being tested in combination with Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in patients with previously untreated metastatic pancreatic cancer. Each Phase 1b clinical trial is designed as a dose-escalation study to primarily assess safety and tolerability. Secondary objectives include a preliminary assessment of efficacy and exploratory objectives include the identification of pharmacodynamic and predictive biomarkers.
"In the pancreatic cancer setting, ipafricept and vantictumab in combination with standard-of-care chemotherapy have demonstrated acceptable safety and encouraging early signs of efficacy and biomarker effects," said Jakob Dupont, M.D., Chief Medical Officer. "The data presented at ESMO, alongside the data presented at ASCO for ipafricept and vantictumab, provide evidence supporting the Phase 2 readiness of each drug. Upon the completion of additional dose cohorts and subsequent follow-up, we look forward to presenting an opt-in package to our partner Bayer for these distinct Wnt pathway inhibitors in the first half of next year."
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=992805
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
In-center self-care hemodialysisis associated with better outcomes than traditional in-center hemodialysis.
While Omada Health’s Prevent program is designed for individuals with prediabetes, it can be adapted to patients who already have diabetes, because the program is built on behavior change and modification, explained Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Silk Road Medical Announces New Medicare Coverage Option for TransCarotid Artery Revascularization (TCAR) Procedures
Via: PR Newswire
Medicare to Cover Procedures within the TCAR Surveillance Project Sponsored by the Society for Vascular Surgery
NEW CAROTID ARTERY STENT PROCEDURE TO BE EVALUATED BY
Edward R Jones, MD, MBA, FACP LaRhondd James, RN Sophid Rosen, PhD
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
Results Expected in the First Half of 2017
NN&I interviewed Leslie Trigg, CEO of Outset Medical, on the company's new Tablo dialysis machine, which is aimed at clinics who want to develop the self-care option for patients.
By: Sarah S. Prichard, MD, FRCP(C) Glenn M. Chertow, MD, MPH
Innovator: Leslie Trigg